If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00343915","ctis_id":"","HasResults":"true","IpdAccessCriteria":"","IpdDescription":"Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site. ","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"true","SharingIpd":"Yes","acronym":"","allocation":"Non-randomized","arm_groups":[{"arm_group_label":"2-Dose Engerix","arm_group_description":"subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.","arm_type":"Experimental"},{"arm_group_label":"3-Dose Engerix","arm_group_description":"subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.","arm_type":"Active Comparator"}],"assignment":"Parallel Assignment","brief_summary":"To evaluate the persistence of antibodies against hepatitis B at 30, 42, 54 and 66 months after the first dose of the hepatitis B primary vaccination course.\nSubjects were aged 11 to 15 years at the time of the primary vaccination course.\nAt the time of enrollment in the present long-term follow-up study subjects were aged 13 to 18 years.\nThe Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Immuno & safety study of GSK Biologicals' thio or preservative free hepatitis B vaccine in subjects aged 11-15 yrs","conditions":[{"DisplayValue":"Hepatitis B","DisplayValue_OneLinkTx":"","InternalValue":"CON_HEPATITIS_B","LookupValue":"Hepatitis B","LookupValue_OneLinkTx":""}],"created_date":"07/23/2020 06:55:29","criteria":"Inclusion Criteria:\n\n - Subjects have participated in primary study HBV-280\n - Written informed consent will be obtained from each subject and/ or parent or guardian of the subject before the blood-sampling visit of each year","detailed_description":"All subjects who participated in the primary study, in which they received either 2 or 3 doses of GSK Biologicals hepatitis B vaccine, and who consented to participate in the long-term follow-up at Month 42 were contacted by the investigators.\nNo additional subjects will be recruited during this long-term follow-up study and no vaccine will be administered.","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 3","display_phase_internal":"PHASE_3","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"267","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"937ce62f-ff65-5556-958c-a07628c46eea","internal":{"content":null,"contentDigest":"9f604fc7457572b3d2b5e180e46e2f78","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria:\n\n - Subjects have participated in primary study HBV-280\n - Written informed consent will be obtained from each subject and/ or parent or guardian of the subject before the blood-sampling visit of each year","interventions":[{"arm_group_label":"2-Dose Engerix","intervention_description":"In the primary study: 2 deep intramuscular injections (Months 0, & 6)","intervention_name":"Engerix™-B (thiomersal-free) 20µg","intervention_type":"Biological/Vaccine"},{"arm_group_label":"3-Dose Engerix","intervention_description":"In the primary study: 3 deep intramuscular injections (months 0, 1 & 6)","intervention_name":"10 μg Engerix™-B (preservative-free)","intervention_type":"Biological/Vaccine"},{"arm_group_label":"2-Dose Engerix","intervention_description":"In the primary study: 1 deep intramuscular injection (month 1)","intervention_name":"placebo","intervention_type":"Biological/Vaccine"}],"interventional_subtype":"Prevention","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":["Persistence","Hepatitis B vaccine"],"last_follow_up_date":"01/10/2008 00:00:00","links":[{"description":"Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.","url":"https://www.clinicalstudydatarequest.com"}],"locations":[{"City":"Bruxelles","Latitude":"50.8503463","CountryDisplay":"Belgium","Longitude":"4.3517211","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"1200","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Kyiv","Latitude":"50.4501","CountryDisplay":"Ukraine","Longitude":"30.5234","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"03038","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sydney","Latitude":"-33.8688197","CountryDisplay":"Australia","Longitude":"151.2092955","Name":"GSK Investigational Site","StateDisplay":"New South Wales","PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Wilrijk","Latitude":"51.1683102","CountryDisplay":"Belgium","Longitude":"4.3942868","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"2610","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"20 years","maximum_age":"20","minimum_age":"13","minimum_age_raw":"13 years","modified_date":"07/23/2020 14:57:44","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs","org_study_id":"101695 Ext. Mth30","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 3","primary_compl_date":"01/10/2008 00:00:00","primary_outcomes":[{"outcome_description":"A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.","outcome_measure":"Number of subjects seroprotected for anti-hepatitis B surface antigen (anti-HBs) antibody.","outcome_time_frame":"At Month 7","outcome_safety_issue":null},{"outcome_description":"A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.","outcome_measure":"Number of subjects seroprotected for anti-hepatitis B surface antigen (anti-HBs) antibody.","outcome_time_frame":"At Month 30, Month 42, Month 54 and Month 66","outcome_safety_issue":null},{"outcome_description":"Antibody titers were summarized by Geometric Mean Concentrations (GMCs) with their 95% CIs.","outcome_measure":"Antibody titers against hepatitis-B virus.","outcome_time_frame":"At Month 30, Month 42, Month 54 and Month 66","outcome_safety_issue":null}],"product_name":"SKF103860","product_name_OneLinkTx":"","secondary_ids":[{"id":"101696","id_type":"Other Identifier","id_domain":"GSK"},{"id":"101697","id_type":"Other Identifier","id_domain":"GSK"},{"id":"101698","id_type":"Other Identifier","id_domain":"GSK"},{"id":"2015-001531-20","id_type":"EudraCT Number","id_domain":""}],"secondary_outcomes":[{"outcome_description":"Antibody titers were summarized by Geometric Mean Concentrations (GMCs) with their 95% CIs.","outcome_measure":"Antibody titers against hepatitis-B virus.","outcome_time_frame":"At Months 1, 2, 6 and 7","outcome_safety_issue":null},{"outcome_description":"A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.","outcome_measure":"Number of subjects seroprotected for anti-HBs antibody.","outcome_time_frame":"At Months 1, 2 and 6","outcome_safety_issue":null},{"outcome_description":"Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.","outcome_measure":"Number of subjects with any and Grade 3 solicited local symptoms","outcome_time_frame":"During the 4-day (Day 0-3) follow-up period after each vaccination and overall","outcome_safety_issue":null},{"outcome_description":"Solicited general symptoms assessed were fatigue, gastrointestinal symptoms, headache, and fever. Any was defined as incidence of the specified symptoms regardless of intensity or relationship to study vaccine. Gastrointestinal symptoms included nausea, vomiting, diarrhea and abdominal pain. Grade 3 fever was defined as fever (axillary temperature) > 38.5°C. Grade 3 symptoms were defined as symptoms which prevented normal everyday activities. Related = general symptom assessed by the investigator as causally related to the vaccination.","outcome_measure":"Number of subjects with any, grade 3 and related solicited general symptoms.","outcome_time_frame":"During the 4-day (Day 0-3) follow-up period after each vaccination and overall","outcome_safety_issue":null},{"outcome_description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","outcome_measure":"Number of subjects reporting any, grade 3 and related unsolicited adverse event (AE).","outcome_time_frame":"During the 31-day (Day 0-30) follow-up period after each vaccination and overall","outcome_safety_issue":null},{"outcome_description":"Serious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.","outcome_measure":"Number of subjects with serious adverse events (SAEs)","outcome_time_frame":"During the entire study period (Month 0 to Month 66)","outcome_safety_issue":null},{"outcome_description":"erious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.","outcome_measure":"Number of subjects with serious adverse events (SAEs).","outcome_time_frame":"At Month 30, Month 42, Month 54 & Month 66","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"04/21/2004 00:00:00","study_type":"Interventional","therapeutic_area":"Vaccines Prophylactic","citations":[{"citation":"Heron L et al. (2007) Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunization of healthy adolescents aged 11-15 years: A randomized controlled trial. Vaccine. 25(15):2817-2822.","is_results_ref":"No","pubmed_id":""},{"citation":"Heron LG et al. (2002) A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine. 20(29-30):3472-3476.","is_results_ref":"No","pubmed_id":""},{"citation":"Van Damme P. et al. (2010) Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11–15 years: a randomised controlled study. BMC Infect Dis.10:357.","is_results_ref":"","pubmed_id":""}],"is_section_801":true}},"pageContext":{"studyId":"101695 Ext. Mth30"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}